COMPARISON OF D-DIMER LEVEL AND PLATELET COUNT IN INDIVIDUALS WITH AND WITHOUT SICKLE CELL ANAEMIA
Keywords:
D-dimer, platelet count, Sickle cell anaemia, steady stateAbstract
Aim: This study aimed to assess the D-dimer levels and platelet count in sickle cell anaemia patients and compare with those of the control subjects.
Materials and Methods: This study is a cross–sectional comparative study which enrolled 58 sickle cell anaemia patients (25 males and 33 females) in a stable state at the Obafemi Awolowo University Teaching Hospital in Ile-Ife, Osun State, Nigeria, as well as 25 healthy controls (11 males and 24 females). Venous blood (4.5 mL) was collected from both the patient and control into a vial containing 0.5 ml of 3.2% trisodium citrate. D-dimer levels was analysed using ELISA method. Platelet counts were determined (from 5ml venous sample collected with EDTA) using haematology autoanalyzer.
Results: There was a significant rise in D-dimer levels in sickle cell patients, with mean values of 1771.86 ng/mL and 1986.00 ng/mL for males and females, respectively, in the steady state compared to the D-dimer levels of controls, with mean values of 199.24 and 322.21 ng/mL for males and females, respectively. Platelet count was significantly higher in SCA patients than in the control subjects. There is perfect correlation between D-dimer and platelet counts in both patients and control (r=1, n=57, P=0.000) and (r=1, n=30, P=0.000)
Conclusion: This study showed the hypercoagulable state and thrombotic risk associated with SCA. The strong correlation between D-dimer levels and platelet counts suggests a potential interplay between platelet activation and coagulation activation in SCA, warranting further investigation into therapeutic interventions targeting these pathways.
Zenodo DOI: https://doi.org/10.5281/zenodo.14543328
References
Hebbel, R. P., & Key, N. S. (2016). Microparticles in sickle cell anaemia: Promise and pitfalls. British Journal of Haematology, 174(1), 16-29.
Kato, G. J., Hebbel, R. P., Steinberg, M. H., Gladwin, M. T. (2017). Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology, 91(2), 927-942.
Martínez, C., Wallenhorst, C., Siu, A., & Tsaras, G. (2020). Elevated D-dimer is associated with acute ischemic stroke in children with sickle cell anaemia. Pediatric Blood & Cancer, 67(7), e28319.
Tsaras, G., Owusu-Ansah, A., Boateng, F. O., & Amoateng-Adjepong, Y. (2009). Complications associated with sickle cell anaemia: a brief narrative review. The American Journal of Medicine, 122(11), 1021-1026.
Wood, K. C., Granger, D. N., & Sickle, C. (2014). Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical and Experimental Pharmacology and Physiology, 41(7), 458-465.
Ataga KI and Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med, 2019;115(9), 721–728.
Uche CL, Abali IO, Ezirim EO, Airaodion AI. Sickle Cell Anemia Contributes to Liver Abnormality. International Journal of Research and Reports in Hematology. 2022;5(2): 122-134
Francis RB. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagu Fibrinolysis, 2021;2:341–353.
Hankins J and Aygun B. Pharmacoltherary in sicke cell disease: State of the art and future prospects. Br J Haematol, 2019;145(3), 296-308.
Foy H, Kondi A.The variability of sickle cell rates in the tribes of Kenya and Southern sudan. Br Med J, 2014;2(6), 1294-1297.
Tomer A, Harker LA, Kasey S and Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med, 2001;137, 398–407.
Lee SP, Ataga KI, Orringer EP and Parise LV. Biologically active CD40 ligand is elevated in sickle cell disease: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc, 2006;26, 1626–1631.
Fakunle EE, Eteng KI, Shokunbi WA. D-dimer levels in Patients with Sickle Cell Disease during bone pain crises and in the steady state. Pathol Lab Med Int 2012; 4:1-5.
Hagger D, Wolf S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with Sickle Cell Disease compared with healthy black controls. Blood Coagul Fibrinolysis 2015; 6:93-9.
Haut MJ, Cowan DH, Harris JW. Platelets function and survival in sickle cell disease. J Lab Clin Med 2023; 82:44-9.
Francis RB. Elevated fibrin D dimer fragment in sickle cell anaemia: Evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis 2019; 19:105-11.
Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: A curious paradox. Am J Med 2013; 115:721-8.
Akinola NO, Stevens SME, Franklin IM, Nash GB, Stuart J. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 2022; 45:902-6.
Ekwere T, Ogunro SP, Akanmu AS. Assessment of some fibrinolytic proteins in sickle cell anemia patients in steady state and in vaso-occlusive crises. J Appl Hematol 2013; 4:131-6.
Philips G, Hartman J, Keller VA, Santiago MA, Pizzo S. Regulation of tissue plasminogen activator in sickle cell anemia. Am J Hematol 2020; 35:167-70.
Philips G, Mitchell LB, Pizzo SV. Defective release of tissue plasminogen activator in patients with sickle cell anemia. Am J Hematol 2018; 29:52-3.
Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. Abnormalities of coagulation and fbrinolysis in homozygous sickle cell disease. Hematol Cell Ther 2016; 38:279-84.
Francis RB Jr. Tissue type plasminogen activator antigen and activity in sickle cell disease. J Clin Pathol 2018; 41:490-3.
Scarano L, Bernardi E, Prandoni P, Sardella C, Rossi L, Carraro P. Accuracy of two newly described D-dimer tests in patients with suspected deep vein thrombosis. Thromb Res 2017; 86:93-9.
Uche CL, Ezirim EO, Abali IO, Airaodion AI. Implication of Nephropathy in Sickle Cell Anaemia. International Journal of Advances in Nephrology Research. 2022;5(1): 74-81
Stief TW. The laboratory diagnosis of the pre-phase of pathologic disseminated intravascular coagulation. Hemostasis Laboratory. 2008; 1:3–19.
Sparkenbaugh E, Pawlinski R. (2013). Prothrombotic aspects of sickle cell disease. Journal of Thrombosis and Haemostasis, 2013;11(5), 844–855.
Ataga KI, Orringer EP, Styles L. Renal abnormalities in sickle cell disease. American Journal of Hematology, 2007;82(5), 339–345.
Ataga, K. I., & Key, N. S. (2017). Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology, 2017(1), 358-363.
Key, N. S., Slungaard, A., Dandelet, L., Nelson, S. C., Moertel, C., Styles, L. A., & Kuypers, F. A. (2018). Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood, 91(10), 4216-4223.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 UCHE CL, CHIKEZIE K, UGWU NI, UGWU CN, AGWU O, OKITE PU, KALU SN, AIRAODION AI, AKINOLA NO
This work is licensed under a Creative Commons Attribution 4.0 International License.
